Baxter International 10-Q 2022-06-30

Filed 2022-07-28. 7 sections, 197K characters. Original on sec.gov · Markdown · JSON

Cover and table of contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________________________________________________________________________

FORM 10-Q

_________________________________________________________________________________

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 1-4448

_________________________________________________________________________________

BAXTER INTERNATIONAL INC.

(Exact name of registrant as specified in its charter)

_________________________________________________________________________________

Delaware36-0781620
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
One Baxter Parkway,Deerfield,Illinois60015
(Address of Principal Executive Offices)(Zip Code)
224.948.2000
(Registrant’s telephone number, including area code)

_________________________________________________________________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $1.00 par valueBAX (NYSE)New York Stock Exchange
Chicago Stock Exchange
0.4% Global Notes due 2024BAX 24New York Stock Exchange
1.3% Global Notes due 2025BAX 25New York Stock Exchange
1.3% Global Notes due 2029BAX 29New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filerxAccelerated filero
Non-accelerated fileroSmaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x

The number of shares of the registrant’s Common Stock, par value $1.00 per share, outstanding as of July 21, 2022 was 503,610,722 shares.

BAXTER INTERNATIONAL INC.

FORM 10-Q

For the quarterly period ended June 30, 2022

TABLE OF CONTENTS

Page Number
PART I.FINANCIAL INFORMATION2
Item 1.Financial Statements (unaudited)2
Condensed Consolidated Balance Sheets2
Condensed Consolidated Statements of Income3
Condensed Consolidated Statements of Comprehensive Income (Loss)4
Condensed Consolidated Statements of Changes in Equity5
Condensed Consolidated Statements of Cash Flows7
Notes to Condensed Consolidated Financial Statements8
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations31
Item 3.Quantitative and Qualitative Disclosures about Market Risk46
Item 4.Controls and Procedures47
PART II.OTHER INFORMATION48
Item 1.Legal Proceedings48
Item 1A.Risk Factors48
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds48
Item 6.Exhibits49
Signature50

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Baxter International Inc.

Condensed Consolidated Balance Sheets (unaudited)

(in millions, except share information)

June 30, 2022December 31, 2021
Current assets:
Cash and cash equivalents$1,852$2,951
Accounts receivable, net of allowances of $125 in 2022 and $122 in 20212,4732,629
Inventories2,6632,453
Prepaid expenses and other current assets894839
Total current assets7,8828,872
Property, plant and equipment, net4,9765,178
Goodwill9,6449,836
Other intangible assets, net7,4597,792
Operating lease right-of-use assets566630
Other non-current assets1,3041,213
Total assets$31,831$33,521
Current liabilities:
Short-term debt$200$301
Current maturities of long-term debt and finance lease obligations208210
Accounts payable1,2821,246
Accrued expenses and other current liabilities2,2262,479
Total current liabilities3,9164,236
Long-term debt and finance lease obligations, less current portion16,27817,149
Operating lease liabilities470522
Other non-current liabilities2,2642,493
Total liabilities22,92824,400
Commitments and contingencies
Equity:
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2022 and 2021683683
Common stock in treasury, at cost,179,687,824 shares in 2022 and 181,879,516 shares in 2021(11,409)(11,488)
Additional contributed capital6,2536,197
Retained earnings17,09917,065
Accumulated other comprehensive (loss) income(3,767)(3,380)
Total Baxter stockholders’ equity8,8599,077
Noncontrolling interests4444
Total equity8,9039,121
Total liabilities and equity$31,831$33,521

The accompanying notes are an integral part of these condensed consolidated financial statements.

Baxter International Inc.

Condensed Consolidated Statements of Income (unaudited)

(in millions, except per share data)

Three months ended June 30,Six months ended June 30,
2022202120222021
Net sales$3,746$3,098$7,453$6,044
Cost of sales2,2931,8654,6523,666
Gross margin1,4531,2332,8012,378
Selling, general and administrative expenses9766752,0281,302
Research and development expenses148139298267
Other operating income, net(11)(5)(28)(5)
Operating income340424503814
Interest expense, net893417468
Other (income) expense, net(44)(2)(60)3
Income before income taxes295392389743
Income tax expense409161142
Net income255301328601
Net income attributable to noncontrolling interests3355
Net income attributable to Baxter stockholders$252$298$323$596
Earnings per share
Basic$0.50$0.59$0.64$1.18
Diluted$0.50$0.59$0.64$1.17
Weighted-average number of shares outstanding
Basic504503503504
Diluted508509508510

The accompanying notes are an integral part of these condensed consolidated financial statements.

Baxter International Inc.

Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited)

(in millions)

Three months ended June 30,Six months ended June 30,
2022202120222021
Net income$255$301$328$601
Other comprehensive income (loss), net of tax:
Currency translation adjustments, net of tax expense (benefit) of $2 and $(4) for the three months ended June 30, 2022 and 2021, respectively, and ($9) and $13 for the six months ended June 30, 2022 and 2021, respectively.(417)88(432)(120)
Pension and other postretirement benefits, net of tax expense of $5 and $3 for the three months ended June 30, 2022 and 2021, respectively, and $8 and $11 for the six months ended June 30, 2022 and 2021, respectively.23113241
Hedging activities, net of tax expense of $4 and $2 for the three months ended June 30, 2022 and 2021, respectively, and $3 and $5 for the six months ended June 30, 2022 and 2021, respectively.1351117
Available-for-sale debt securities, net of tax expense of zero for the three months ended June 30, 2022 and 2021, respectively, and $1 and zero for the six months ended June 30, 2022 and 2021, respectively.1—2—
Total other comprehensive income (loss), net of tax(380)104(387)(62)
Comprehensive income (loss)(125)405(59)539
Less: Comprehensive income attributable to noncontrolling interests3355
Comprehensive income (loss) attributable to Baxter stockholders$(128)$402$(64)$534

The accompanying notes are an integral part of these condensed consolidated financial statements.

Baxter International Inc.

Condensed Consolidated Statements of Changes in Equity (unaudited)

(in millions)

For the three months ended June 30, 2022
Baxter International Inc. stockh

Showing the first 8K of 112K characters. Open the full section

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Refer to our Annual Report on Form 10-K for the year ended December 31, 2021 for management’s discussion and analysis of our financial condition and results of operations. The following is management’s discussion and analysis of our financial condition and results of operations for the three and six months ended June 30, 2022 and 2021.

RESULTS OF OPERATIONS

Net income attributable to Baxter stockholders for the three and six months ended June 30, 2022 totaled $252 million, or $0.50 per diluted share, and $323 million, or $0.64 per diluted share, compared to $298 million, or $0.59 per diluted share, and $596 million, or $1.17 per diluted share, for the three and six months ended June 30, 2021. The first quarter of 2022 was the first full quarter reflecting Hillrom results of operations after the December 13, 2021 acquisition. Net income for the three and six months ended June 30, 2022 included special items which decreased net income by $191 million and $591 million, respectively, or $0.37 and $1.16 per diluted share, respectively, as further discussed below. Net income for the three and six months ended June 30, 2021 included special items which decreased net income by $111 million and $199 million, respectively, or $0.21 and $0.39 per diluted share, respectively, as further discussed below.

Special Items

The following table provides a summary of our special items and the related impact by line item on our results for the three and six months ended June 30, 2022 and 2021.

Three months ended June 30,Six months ended June 30,
(in millions)2022202120222021
Gross Margin
Intangible asset amortization expense$(112)$(67)$(234)$(131)
Business optimization items1(6)(10)(8)(31)
Acquisition and integration expenses2(9)—(173)—
European medical devices regulation3(12)(11)(23)(19)
Product-related items5——(23)—
Total Special Items$(139)$(88)$(461)$(181)
Impact on Gross Margin Ratio(3.7 pts)(2.8 pts)(6.2 pts)(3.0 pts)
Selling, General and Administrative (SG&A) Expenses
Intangible asset amortization expense$81$—$176$—
Business optimization items136811414
Acquisition and integration expenses2201442
Investigation and related costs4—17—28
Total Special Items$137$26$334$44
Impact on SG&A Ratio3.7 pts0.9 pts4.5 pts0.7 pts
Research and Development (R&D) Expenses
Business optimization items1$—$—$1$—
Total Special Items$—$—$1$—
Impact on R&D Ratio0.0 pts0.0 pts0.0 pts0.0 pts
Other Operating Income, net
Acquisition and integration expenses2$(11)$(5)$(28)$(5)
Total Special Items$(11)$(5)$(28)$(5)
Other Income (Expense), net
Pension curtailment6$(11)$—$(11)$—
Total Special Items$(11)$—$(11)$—
Income Tax Expense
Tax matters7$—$22$—$22
Tax effects of special items8(63)(20)(166)(43)
Total Special Items$(63)$2$(166)$(21)
Impact on Effective Tax Rate(5.2 pts)5.2 pts(4.1 pts)2.1 pts

Intangible asset amortization expense, which increased significantly from the prior year due to the Hillrom acquisition, is identified as a special item to facilitate an evaluation of current and past operating performance and is consistent with how management and our Board of Directors assess performance. Additional special items are identified above because they are highly variable, difficult to predict and of a size that may substantially impact our reported results of operations for the period. Management believes that providing the separate impact of those items may provide a more complete understanding and facilitate a fuller analysis of our results of operations, particularly in evaluating performance from one period to another.

1In 2022 and 2021, our results were impacted by costs associated with our execution of programs to optimize our organization and cost structure. These actions included streamlining our international operations, rationalizing our manufacturing and distribution facilities, reducing our general and administrative infrastructure, re-aligning certain R&D activities and cancelling certain R&D programs. In the current period, restructuring charges include actions taken in connection with our integration of Hillrom, which we acquired in

December 2021. Our results in 2022 included business optimization charges of $42 million in the second quarter and $123 million in the first half. Our results in 2021 included business optimization charges of $18 million in the second quarter and $45 million in the first half. Refer to Note 10 in Item 1 of this Quarterly Report on Form 10-Q for further information regarding these charges and related liabilities.

2Our results in 2022 included $18 million in the second quarter and $189 million in the first half of acquisition and integration-related expenses. Those costs included $29 million in the second quarter and $217 million in the first half related to our acquisition of Hillrom, primarily reflecting $159 million of incremental costs of sales in the first half from the fair value step-ups on acquired Hillrom inventory that was sold in the first quarter. We have not incurred and we do not expect to incur significant incremental cost of sales from those inventory fair value step-ups beyond what was recognized in the first quarter 2022. Other integration expenses in the current period included third party consulting costs related to our integration

Showing the first 8K of 66K characters. Open the full section

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Currency Risk

We are primarily exposed to foreign exchange risk with respect to revenues generated outside of the United States denominated in the Euro, British Pound, Chinese Renminbi, Korean Won, Australian Dollar, Canadian Dollar, Japanese Yen, Colombian Peso, Brazilian Real, Mexican Peso, Indian Rupee and Swedish Krona. We manage our foreign currency exposures on a consolidated basis, which allows us to net exposures and take advantage of any natural offsets. In addition, we use derivative and nonderivative financial instruments to further reduce the net exposure to foreign exchange. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and stockholders’ equity volatility relating to foreign exchange. However, we don't hedge our entire foreign exchange exposure and are still subject to earnings and stockholders' equity volatility relating to foreign exchange risk. Financial market and currency volatility may limit our ability to cost-effectively hedge these exposures.

We use options and forwards to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities denominated in foreign currencies. The maximum term over which we have cash flow hedge contracts in place related to foreign exchange risk on forecasted transactions as of June 30, 2022 is 12 months. We also enter into derivative instruments to hedge foreign exchange risk on certain intra-company and third-party receivables and payables and debt denominated in foreign currencies.

As part of our risk-management program, we perform sensitivity analyses to assess potential changes in the fair value of our foreign exchange instruments relating to hypothetical and reasonably possible near-term movements in foreign exchange rates.

A sensitivity analysis of changes in the fair value of foreign exchange contracts outstanding as of June 30, 2022, while not predictive in nature, indicated that if the U.S. Dollar uniformly weakened by 10% against all currencies, the net pre-tax asset balance of $5 million with respect to those contracts would change by $57 million.

The sensitivity analysis model recalculates the fair value of the foreign exchange contracts outstanding as of June 30, 2022 by replacing the actual exchange rates as of June 30, 2022 with exchange rates that are 10% weaker compared to the actual exchange rates for each applicable currency. All other factors are held constant. These sensitivity analyses disregard the possibility that currency exchange rates can move in opposite directions and that gains from one currency may or may not be offset by losses from another currency. The analyses also disregard the offsetting change in value of the underlying hedged transactions and balances.

In February 2022, the three-year cumulative inflation rate in Turkey exceeded 100 percent. As a result, on April 1, 2022, we began reporting the results of our subsidiary in that jurisdiction using highly inflationary accounting, which requires that the functional currency of the entity be changed to the reporting currency of its parent. As of June 30, 2022, our subsidiary in Turkey had net monetary assets of $40 million.

Our subsidiary in Argentina is reported using highly inflationary accounting effective July 1, 2018. Changes in the value of the Argentine Peso applied to our peso-denominated net monetary asset positions are recorded in income at the time of the change. As of June 30, 2022, our net monetary assets denominated in Argentine Pesos are not significant.

Interest Rate and Other Risks

Refer to the caption “Interest Rate and Other Risks” in the “Financial Instrument Market Risk” section of the 2021 Annual Report. There were no significant changes during the quarter ended June 30, 2022.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of June 30, 2022. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2022.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

The information in Part I, Item 1, Note 6 is incorporated herein by reference.

Item 1A. Risk Factors

We do not believe that there have been any material changes to the risk factors previously disclosed in our 2021 Annual Report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

PeriodTotal number of shares purchased (1)Average price paid per shareTotal number of shares purchased as part of publicly announced program(1)Approximate dollar value of shares that may yet be purchased under the program(1)
April 1, 2022 through April 30, 2022—$——
May 1, 2022 through May 31, 2022—$——
June 1, 2022 through June 30, 2022125,000$64.91125,000
Total125,000$64.91125,000$1,289,019,296

(1) In July 2012, we announced that our Board of Directors authorized us to repurchase up to $2.0 billion of our common stock on the open market or in private transactions. The Board of Directors increased this authority by an additional $1.5 billion in each of November 2016 and February 2018, by an additional $2.0 billion in November 2018 and by an additional $1.5 billion in October 2020. During the second quarter of 2022, we repurchased approximately 0.1 million shares for $8 million pursuant to this authority through a Rule 10b5-1 purchase plan. We had $1.3 billion remaining under this program as of June 30, 2022. This program does not have an expiration date.

Item 6. Exhibits

Exhibit Index:

Exhibit NumberDescription
3.1Amended and Restated Certificate of Incorporation of Baxter International Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, filed on May 6, 2022).
3.2Bylaws, as amended and restated on May 5, 2022 (incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K, filed on May 6, 2022).
4.1Indenture, dated July 29, 2021, between Baxter International Inc. and U.S. Bank Trust Company, National Association, as successor in interest of U.S. Bank National Association, as trustee for the debt securities (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form S-3ASR, filed on April 28, 2022).
31.1*Certification of Chief Executive Officer Pursuant to Rules 13a-14 (a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
31.2*Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
32.1*Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*XBRL Instance Document
101.SCH*XBRL Taxonomy Extension Schema Document
101.CAL*XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*XBRL Taxonomy Extension Label Linkbase Document
101.PRE*XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*XBRL Taxonomy Extension Definition Linkbase Document
104*Cover Page Interactive Data File (formatted as Inline XBRL and contained within the Inline XBRL Instance Document in Exhibit 101)

  • Filed herewith.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BAXTER INTERNATIONAL INC.
(Registrant)
Date: July 28, 2022
By:/s/ James K. Saccaro
James K. Saccaro Executive Vice President and Chief Financial Officer (duly authorized officer and principal financial officer)